Provided by Tiger Trade Technology Pte. Ltd.

Kymera Therapeutics, Inc.

114.96
-2.0400-1.74%
Post-market: 114.960.00000.00%19:30 EDT
Volume:574.19K
Turnover:66.17M
Market Cap:9.56B
PE:-35.79
High:119.93
Open:118.40
Low:113.74
Close:117.00
52wk High:130.05
52wk Low:45.84
Shares:83.15M
Float Shares:64.87M
Volume Ratio:0.92
T/O Rate:0.89%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.2122
EPS(LYR):-3.6900
ROE:-24.15%
ROA:-15.59%
PB:6.33
PE(LYR):-31.15

Loading ...

Major Investor Makes Dramatic Move in Kymera Therapeutics Holdings

TIPRANKS
·
Jun 27

BVF Partners Reports Kymera Therapeutics Share Disposal Worth $173.84 Million

Reuters
·
Jun 27

Movement Alert|Kymera Therapeutics Falls 7.48% in Regular Trading, Trading at $107.68

Market Focus
·
Jun 27

Truist Securities Adjusts Kymera Therapeutics PT to $136 From $116, Maintains Buy Rating

MT Newswires Live
·
Jun 26

Kymera Therapeutics price target raised to $129 from $106 at Canaccord

TIPRANKS
·
Jun 26

Kymera Therapeutics Chief Business Officer Noah Goodman Disposes of 5,000 Shares for $570,000

Reuters
·
Jun 26

Sector Update: Healthcare

MT Newswires Live
·
Jun 26

Top Midday Gainers

MT Newswires Live
·
Jun 26

Kymera Therapeutics Price Target Maintained with a $134.00/share by BTIG

Dow Jones
·
Jun 26

Kymera Therapeutics Stock (KYMR) Soars on Accelerated Clinical Trial Enrollment

TIPRANKS
·
Jun 25

Kymera Therapeutics Shares Jump After Accelerating Kt-621 Trial Timeline

Dow Jones
·
Jun 25

Kymera Therapeutics rises 18.6%

TIPRANKS
·
Jun 25

Analysts Are Bullish on Top Healthcare Stocks: Alpha Teknova (TKNO), Kymera Therapeutics (KYMR)

TIPRANKS
·
Jun 25

Shares of Kymera Therapeutics up 10.2% Premarket After Co Completes Enrollment for Mid-stage Eczema Trial

THOMSON REUTERS
·
Jun 25

Kymera Rises on Accelerated Trial Timeline for Experimental Eczema Drug

Reuters
·
Jun 25

Kymera Therapeutics Advances KT-621 Development With Phase 2b Enrollment Completion

MT Newswires Live
·
Jun 25

Kymera Therapeutics - Phase 3 Trials in Atopic Dermatitis Expected to Initiate by Mid-2027

THOMSON REUTERS
·
Jun 25

Kymera Therapeutics - Kt-621 Breadth Phase 2B Asthma Trial Data Expected in Late 2027

THOMSON REUTERS
·
Jun 25

Kymera Therapeutics Completes Enrollment in the Phase 2B Broaden2 Trial of Kt-621 in Atopic Dermatitis with Topline Data by Year-end 2026

THOMSON REUTERS
·
Jun 25

Kymera Therapeutics Shareholders Elect Booth, Mainolfi, Maraganore, Ridloff as Class III Directors

Reuters
·
Jun 25